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Abstract At present, no treatment recommendations can
be made for compulsive buying disorder. Recent studies
have found evidence for the efficacy of psychotherapeutic
options, but less is known regarding the best pharmaco-
logic treatment. The purpose of this review is to present
and analyze the available published evidence on the
pharmacological treatment of compulsive buying disorder.
To achieve this, we conducted a review of studies focusing
on the pharmacological treatment of compulsive buying by
searching the PubMed/MEDLINE database. Selection cri-
teria were applied, and 21 studies were identified. Phar-
macological classes reported included antidepressants,
mood stabilizers, opioid antagonists, second-generation
antipsychotics, and N-methyl-D-aspartate receptor antago-
nists. We found only placebo-controlled trials for fluvox-
amine; none showed effectiveness against placebo. Three
open-label trials reported clinical improvement with
citalopram; one was followed by a double-blind discon-
tinuation. Escitalopram was effective in an open-label trial
but did not show efficacy in the double-blind phase.
Memantine was identified as effective in a pilot open-label
study. Fluoxetine, bupropion, nortriptyline, clomipramine,
topiramate and naltrexone were only reported to be effec-
tive in clinical cases. According to the available literature,
there is no evidence to propose a specific pharmacologic
agent for compulsive buying disorder. Future research is
required for a better understanding of both pathogenesis
and treatment of this disorder.
Key Points
Conducting clinical trials of treatments for
compulsive buying disorder is challenging, and
many limitations of current studies have been
highlighted.
The heterogeneity of pharmacologic treatment
options reported to be effective has raised many
questions regarding our current understanding of
compulsive buying disorder.
Further studies are required to examine the
effectiveness of pharmacologic options against
placebo and other treatments.
1 Introduction
Compulsive buying disorder (CBD) is a syndrome char-
acterized by a maladaptive preoccupation with buying or
shopping, or maladaptive buying or shopping impulses or
behavior, that result in relevant negative personal, social,
or financial consequences [1, 2]. It is clinically recognized
by repetitive or compulsive engagement in a behavior
despite negative consequences, high impulsivity level, and
diminished control over the problematic behavior [3, 4].
Based on Esquirol’s concept of monomania, both Krae-
pelin [5] and Bleuler [6] referred to CBD in their textbooks
as a form of pathological impulse. The latter grouped
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compulsive buying alongside kleptomania and pyromania
as an example of a ‘‘reactive impulse’’ or ‘‘impulsive
insanity.’’ More recently, the disorder has been receiving
greater attention in a discussion shared by clinicians, psy-
chiatry, and consumer researchers [7].
Given the multidimensional nature of CBD, its classi-
fication is controversial and remains elusive, with
researchers linking it to impulse control disorders, addic-
tive disorders, obsessive-compulsive disorder, or the mood
spectrum [8, 9]. Other researchers have criticized both the
labeling of it as an illness and the trend to medicalize
behavioral problems [10, 11]. In the perspective of a cul-
tural background in the etiology of psychiatric disorders,
CBD is a good model: without the act of buying developed
in ancient Greece, and the consumer-driven economy of
Western societies, no disorder would have been developed
and/or maintained [11, 12]. Regarding this topic, particular
attention has been given to how the digital technology age
has been shaping and enhancing consumer behavior, with
authors starting to look to online compulsive buying as a
distinctive behavioral disorder [13, 14].
CBD is not included in current psychiatric nosological
systems: Diagnostic and Statistical Manual of Mental
Disorders, fifth edition (DSM-V) and International Sta-
tistical Classification of Diseases and Related Health
Problems, tenth edition (ICD-10) [15, 16]. As there is no
consistent concept for diagnosis, for the present work we
use the diagnostic criteria of McElroy et al. [1] (Table 1).
CBD is probably a common disorder in high-income
countries, with representative surveys from the USA and
Germany indicating a prevalence of between 6 and 7 % in
adults. In a recent meta-analysis, Maraz et al. [17] esti-
mated a prevalence of around 5 % in the populations
studied. A female predominance has been suggested, but
there is no consensus on that issue [18, 19]. Koran et al.
[20] reported an essentially equal sex distribution in a large
representative study [21]. Several studies have found rel-
evant psychiatric comorbidities associated with CBD [22],
with mood and anxiety disorders, impulse control disor-
ders, substance abuse, and eating disorders BEING the
most frequently reported [23–25]. The relevant burden of
this interaction has been discussed in the literature but
deserves to be clarified.
The etiology of CBD is unknown, with authors sug-
gesting developmental, neurobiological, and cultural causal
factors [26]. Neurobiological theories have proposed the
presence of a disturbed serotoninergic, dopaminergic, or
opioid neurotransmission, but research supporting these
theories is limited. A genetic study failed to show differ-
ences in DNA sequence polymorphisms between the
serotonin transporter (5-HTT) of CBD patients and controls
[27]. Dopamine has been theorized to play a role in ‘‘re-
ward dependence’’, but the dopamine D2 receptor gene
(DRD2) that has been implicated in other addictive
behaviors has not been studied in CBD [28, 29]. A study of
the neural correlates of compulsive buying was conducted
using functional magnetic resonance imaging, and the
results showed significant differences between non-com-
pulsive and compulsive buyers regarding brain activity in
regions known to be involved in decision making [30]. In
spite of increasing research, the neurobiological under-
pinnings of CBD remain elusive. Psychotropic medication
has been widely used in CBD, supported mainly by
observed similarities with phenotypes of other disorders
treated with these medications (e.g., obsessive compulsive
disorder [OCD]). Despite this widespread use, there has
been limited study and reporting of the effectiveness of
pharmacological treatment, such that responses to these
drugs remain unclear [31, 32]. In contrast, individual and
group psychotherapy, mostly cognitive–behavioral therapy
(CBT), has been shown to be effective. Authors recognize
it is necessary to extend the investigation in the field of
psychoactive drugs [33].
The objectives of this work were to present and ana-
lyze the available published evidence on the pharmaco-
logical treatment of CBD and discuss pharmacological
treatment options. We conducted a search of published
articles, with no time restriction, using the PubMed/
MEDLINE database in July 2015. Keywords included
oniomania, compulsive/impulsive buying, compulsive/
impulsive shopping, shopping/buying addiction crossed
with the term treatment.
Table 1 Diagnostic criteria for compulsive buying disorder
(A) Maladaptive preoccupation with buying or shopping, or maladaptive buying or shopping impulses or behavior, as indicated by at least one
of the following:
1. Frequent preoccupation with buying or impulses to buy that is/are experienced as irresistible, intrusive, and/or senseless
2. Frequent buying of more than can be afforded, frequent buying of items that are not needed, or shopping for longer periods of time than
intended
(B) The buying preoccupations, impulses, or behaviors cause marked distress, are time consuming, significantly interfere with social or
occupational functioning, or result in financial problems (e.g., indebtedness or bankruptcy)
(C) The excessive buying or shopping behavior does not occur exclusively during periods of hypomania or mania
Reproduced from McElroy et al. [1]
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2 Literature Identified
A total of 420 references were found through the PubMed/
MEDLINE search; 163 duplicate articles were discarded,
21 references in languages other than Portuguese, English,
and Spanish were also excluded, and 218 were removed
through abstract analysis for not meeting the inclusion
criteria (related to Parkinson and dopamine [72 articles],
related to compulsive buying disorder other than clinical
trials or case studies [63 articles], limited to psychothera-
peutic strategies [nine articles], and not related to the
pharmacological treatment of CBD [74 articles]). A total of
21 articles were included in the review and carefully ana-
lyzed: eight clinical trials (two placebo-controlled, two
open-label followed by double-blind discontinuation, and
four open-label trials) and ten case studies (nine case
reports and one case series). Other relevant articles were
identified through the reference lists of retrieved articles
(Fig. 1).
The demographic and clinical features of the studies are
shown in Tables 2 and 3. Articles selected were published
in the last three decades (1991–2014). The average sample
size in the clinical trials was 23.75 subjects, and follow-up
time ranged from 9 weeks to 12 months. Lifetime psychi-
atric comorbidities were reported in almost all studies
analyzed. The overall sex analysis showed a female
predominance.
Pharmacological classes reported included antidepres-
sants, mood stabilizers, opioid antagonists, second-gener-
ation antipsychotics, and N-methyl-D-aspartate receptor
antagonists. Fluvoxamine was used in six studies, two of
which were placebo-controlled trials. Citalopram was tes-
ted in three open-label trials, one of which was followed by
a double-blind discontinuation. Escitalopram and meman-
tine were also studied in clinical trials. The effects of the
antidepressants fluoxetine, bupropion, nortriptyline, and
clomipramine have only been reported in isolated clinical
cases. The same was noted with topiramate and naltrexone
(Tables 2, 3).
2.1 Antidepressants
Seven studies reported an improvement in and/or remission
of the compulsive buying behavior with antidepressant
treatment, mostly serotonin reuptake inhibitors (SRIs) [1,
12, 14, 19, 34, 35, 55].
Mc Elroy et al. [34] was the first to report in the lit-
erature a clinical study of a pharmacological treatment
for CBD. Based on the positive response to antidepres-
sants seen in a number of psychiatric disorders charac-
terized by the compulsive performance of senseless or
harmful behaviors, the author reported that the
compulsive buying behavior of three women with
comorbid mood and anxiety disorders partially (one) or
fully (two) remitted with treatment with fluoxetine,
bupropion, and nortriptyline [34]. Later, in 1994, Mc
Elroy et al. [1] assessed 20 compulsive buyers and found
that 69 % of the 13 treated with antidepressants, mostly
SRIs in combination with mood stabilizers, showed
reduction or remission of their buying symptoms. Two
more cases of CBD in psychiatric patients in whom
pathological buying behavior disappeared with the
treatment of depression were reported by Lejoyeux et al.
[14]. Clomipramine 150 mg/day was used in one patient;
the other agent was not reported [14].
420 arcles idenﬁed 
through database 
selecon  
257 screened  
163 duplicates removed 
236 assessed for eligibility  
21 excluded [language] 
72 arcles related to Parkinson's 
disease and dopamine 
63 arcles about CBD other than 
clinical trials or case studies 
 9 arcles limited to the 
psychotherapeuc strategies  
 74 references not related to the 
main purpose of review 
18 included   
3 studies added through 
reference lists  
A total of 21 arcles included  
Fig. 1 The process for studies selection. CBD compulsive buying
disorder
Pharmacologic Treatment for Compulsive Buying Disorder
T
a
b
le
2
T
re
at
m
en
t
o
p
ti
o
n
s
fo
r
co
m
p
u
ls
iv
e
b
u
y
in
g
d
is
o
rd
er
as
re
p
o
rt
ed
in
ca
se
se
ri
es
an
d
ca
se
re
p
o
rt
s
T
y
p
e
o
f
st
u
d
y
an
d
st
u
d
y
d
et
ai
ls
S
am
p
le
A
g
e
(y
ea
rs
)
C
o
m
o
rb
id
it
ie
s
P
re
v
io
u
s
tr
ea
tm
en
t
M
ea
su
re
s
T
h
er
ap
eu
ti
c
o
p
ti
o
n
S
id
e
ef
fe
ct
s
O
u
tc
o
m
e
C
as
e
se
ri
es
M
cE
lr
o
y
et
al
.
[1
]
N
=
2
0
(1
6
$,
4
#
)
3
9
±
1
1
M
o
o
d
an
d
an
x
ie
ty
d
is
o
rd
er
s,
IC
D
,
ea
ti
n
g
d
is
o
rd
er
s
N
R
N
R
A
D
s
?
m
o
o
d
st
ab
il
iz
er
s,
B
U
P
?
li
th
iu
m
,
F
L
U
?
V
A
L
,
F
L
U
?
li
th
iu
m
H
y
p
o
m
an
ia
in
d
u
ct
io
n
6
9
%
im
p
ro
v
ed
o
r
re
m
it
te
d
C
as
e
re
p
o
rt
s
M
c
E
lr
o
y
et
al
.
[3
4
]
N
=
3
(3
$,
0
#
)
3
3
–
4
5
M
o
o
d
an
d
an
x
ie
ty
d
is
o
rd
er
s,
so
m
at
o
fo
rm
d
is
o
rd
er
s,
su
b
st
an
ce
ab
u
se
d
is
o
rd
er
s,
ea
ti
n
g
d
is
o
rd
er
s
Y
es
F
L
U
4
0
m
g
/d
ay
,
B
U
P
u
p
to
1
0
0
m
g
/d
ay
[
N
O
R
u
p
to
1
0
0
m
g
/d
ay
[
F
L
U
2
0
m
g
/d
ay
[
F
L
U
2
0
m
g
/3
d
ay
s,
F
L
U
8
0
m
g
/d
ay
H
ea
d
ac
h
e,
w
ei
g
h
t
g
ai
n
,
h
y
p
o
m
an
ia
in
d
u
ct
io
n
A
ll
im
p
ro
v
ed
an
d
tw
o
fu
ll
y
re
m
it
te
d
L
ej
o
y
eu
x
et
al
.
[1
4
]
N
=
2
(1
$,
1
#
)
4
8
,
5
1
M
o
o
d
d
is
o
rd
er
s,
p
er
so
n
al
it
y
d
is
o
rd
er
s
N
R
N
R
C
L
O
1
5
0
m
g
/d
ay
N
R
T
re
at
m
en
t
o
f
d
ep
re
ss
io
n
le
d
to
re
m
is
si
o
n
K
im
[2
1
]
1
$
4
6
S
u
b
st
an
ce
ab
u
se
d
is
o
rd
er
,
ea
ti
n
g
d
is
o
rd
er
N
o
N
R
N
A
L
5
0
m
g
/d
ay
[
1
0
0
m
g
/d
ay
D
ia
rr
h
ea
an
d
n
au
se
a
Im
p
ro
v
em
en
t
in
se
v
er
al
d
ay
s
an
d
re
m
is
si
o
n
G
ra
n
t
[2
5
]
N
=
3
(2
$,
1
#
)
3
2
N
R
Y
es
N
R
N
A
L
u
p
to
1
0
0
m
g
/d
ay
N
au
se
a
R
em
it
te
d
4
3
N
o
N
o
N
R
N
A
L
u
p
to
2
0
0
m
g
/d
ay
N
au
se
a
P
ar
ti
al
ly
re
m
it
te
d
2
8
N
o
N
o
N
R
N
A
L
u
p
to
1
5
0
m
g
/d
ay
H
ea
d
ac
h
e
R
em
it
te
d
M
ar
ci
n
k
o
et
al
.
[5
5
]
1
$
3
2
N
R
N
R
Y
B
O
C
S
-S
V
,
C
G
I-
I
F
L
U
V
1
0
0
m
g
u
p
to
tw
ic
e
a
d
ay
?
C
B
T
N
R
In
re
m
is
si
o
n
d
u
ri
n
g
a
1
2
-m
o
n
th
fo
ll
o
w
-u
p
M
ar
ci
n
k
o
et
al
.
[3
5
]
1
$
3
3
E
at
in
g
d
is
o
rd
er
s
N
o
N
R
F
L
U
V
u
p
to
1
5
0
m
g
/d
ay
?
D
IA
?
P
P
N
R
Im
p
ro
v
em
en
t
af
te
r
4
w
ee
k
s;
1
-y
ea
r
fo
ll
o
w
-u
p
w
it
h
o
u
t
re
cu
rr
en
ce
1
$
4
1
E
at
in
g
d
is
o
rd
er
s
N
o
N
R
F
L
U
V
u
p
to
2
0
0
m
g
/d
ay
?
P
P
N
R
Im
p
ro
v
em
en
t
af
te
r
3
w
ee
k
s;
1
-y
ea
r
fo
ll
o
w
-u
p
w
it
h
o
u
t
re
cu
rr
en
ce
G
u
zm
an
et
al
.
[4
4
]
1
$
3
7
M
o
o
d
d
is
o
rd
er
s
Y
es
B
D
I
T
O
P
u
p
to
1
5
0
m
g
/d
ay
.
V
E
N
d
is
co
n
ti
n
u
ed
N
R
R
em
is
si
o
n
af
te
r
1
m
o
n
th
T
av
ar
es
et
al
.
[1
2
]
1
$
4
8
M
o
o
d
d
is
o
rd
er
s
N
R
N
R
P
P
,
p
sy
ch
o
ed
u
ca
ti
o
n
,
cr
ed
it
ca
rd
ca
n
ce
ll
at
io
n
,
F
L
U
2
0
m
g
/d
ay
fo
r
d
ep
re
ss
io
n
N
R
R
em
is
si
o
n
af
te
r
5
w
ee
k
s
D
i
N
ic
o
la
et
al
.
[3
]
1
#
4
7
M
o
o
d
d
is
o
rd
er
s
(B
D
I)
,
o
b
li
g
at
o
ry
p
h
y
si
ca
l
ex
er
ci
se
Y
es
H
R
S
D
,
Y
M
R
S
,
H
A
R
S
,
C
B
S
,
E
A
I,
B
IS
Q
U
E
u
p
to
6
0
0
m
g
/d
ay
N
R
Im
p
ro
v
ed
af
te
r
4
w
ee
k
s;
re
m
is
si
o
n
at
2
4
th
w
ee
k
C. Soares et al.
2.1.1 Fluvoxamine
Prompted by case reports suggesting that patients with
CBD improved when receiving SRIs, and according to the
comparison between this disorder and OCD, Black et al.
[36] hypothesized that patients with CBD would improve
in a similar way to that observed with OCD patients. An
open-label trial of fluvoxamine up to 300 mg/day was
conducted, in which nine of ten subjects showed clinical
improvement and a tendency to relapse when the treatment
was discontinued at the end of a 9-week protocol [36].
Based on this success, Black et al. [37] later conducted a
double-blind protocol to test whether fluvoxamine up to
300 mg/day was better than placebo. The authors found no
significant differences between fluvoxamine- and placebo-
treated subjects on any of the outcome measures, with the
exception that fluvoxamine recipients achieved greater
improvement than the placebo recipients on the Maudsley
Obsessive-compulsive Inventory (MOI) [37].
Fluvoxamine efficacy was also evaluated in a double-
blind trial of patients with compulsive buying by Ninan
et al. [38]. In this study, fluvoxamine up to 300 mg/day
significantly reduced compulsive buying during the time of
active treatment, but there was a similar outcome with the
placebo. Although patients who demonstrated a [50 %
improvement in Yale-Brown Obsessive-Compulsive Scale-
Shopping Version (YBOCS-SV) scores in a 1-week single-
blind placebo treatment had been excluded, there was a
high placebo response rate that authors attribute to the
effect of the behavioral monitoring [38].
2.1.2 Citalopram and Escitalopram
Following the promising results reported with fluvoxamine,
Koran et al. [39] tested the effectiveness of citalopram,
another selective SRI. Patients treated with citalopram up
to 60 mg/day experienced rapid, marked, and sustained
improvements during a 6-month follow-up period [39]. A
dose–response relationship was not present. The study was
limited by the small sample, the absence of a placebo
control group, and a reliance on self-reported behavior by
subjects. There was a significant correlation between the
change in YBOCS-SV and Montgomery-A˚sberg Depres-
sion Rating Scale (MADRS) scores, which suggested that
the improvement in compulsive buying behavior was due
to the treatment of subclinical depressive symptoms.
However, several patients achieved a sustained therapeutic
response at doses lower than those used to treat depression.
Another work by Koran et al. [40] documented a 7-week
open-label trial followed by a 9-week double-blind, pla-
cebo-controlled discontinuation trial. Of the 15 responders
who entered the double-blind treatment phase, five of eight
(63 %) randomized to placebo relapsed compared withT
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none of seven (0 %) randomized to continue taking
citalopram. The reduction in shopping compulsions was
independent of improvement in formally diagnosed
comorbid mood disorders but positively correlated with
improvement in depressive symptoms in both the open and
blind phases of the study. The authors concluded that
citalopram up to 60 mg/day is an effective treatment for
compulsive buying but highlight the need for placebo-
controlled trials [40].
An identical study design was further conducted to test
the effectiveness of escitalopram 10 or 20 mg/day, the
active isomer in the racemic mixture of citalopram [41].
The double-blind treatment phase results failed to confirm
that the open-label escitalopram response was a true drug
effect.
Aboujaoude et al. [42] reported the first long-term
follow-up of patients with CBD in a cohort that had
completed up to 3 months of open-label treatment with
citalopram 20–60 mg/day. No clear association was found
between taking citalopram and remission status, but the
authors proposed that these findings do not necessarily
indicate a placebo response to citalopram. Once subjects
in the open-label trial gained an awareness of the disor-
der, they became optimistic about their ability to control
it, developing new shopping strategies and motivation
because of the benefits of remission. Alternatively, they
speculate that 3 months of citalopram treatment can nor-
malize serotoninergic neural pathways. The authors con-
cluded that an acute response to citalopram predicts a
greater likelihood of continued remission over 1 year
[42].
2.2 Opioid Antagonists
2.2.1 Naltrexone
Naltrexone, an opioid antagonist that inhibits dopamine
release in the nucleus accumbens, was reported to reduce
urges to shop and compulsive shopping behavior by Kim
[21]. The authors prescribed the drug for up to 9 months to
15 patients with impulse-control disorders, including in this
group patients with CBD [21].
Later, Grant [25] reported three cases of patients with
CBD without any other comorbidity who were successfully
treated with high doses of naltrexone (up to 100, 150, and
200 mg/day). The author suggested that the antagonism of
the system that processes pleasure and pain can diminish an
essential feature of CBD: the failure to resist an impulse to
purchase despite harmful consequences [25]. The author
advised that liver function tests should be monitored in all
patients taking naltrexone.
No open or double-blind trials were conducted with this
agent to confirm these findings.T
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2.3 Mood Stabilizers
2.3.1 Topiramate
Two case reports were published on the treatment of CBD
with topiramate [43, 44]. Topiramate is an active anti-
convulsant whose mechanisms of action include potentia-
tion of gamma-aminobutyric acid (GABA) to activate
GABA-A receptors and antagonism of glutamate at specific
receptors. It has been shown to be beneficial for a variety of
psychiatric illnesses, such as affective disorders, eating
disorders, addictive disorders (including alcoholism),
posttraumatic stress disorder, and OCD [45–49]. The use of
topiramate up to 150 mg/day in CBD was first suggested
by Guzam et al. [44], who highlighted the role of this agent
in the treatment of addictive behavior disorders. Later, Ye
et al. [43] reported another case treated in a similar way, in
which a patient maintained progress for more than half a
year. The improvement in compulsive buying behavior was
independent of comorbid conditions; the advantage with
topiramate is that it can be quickly titrated [43]. The
authors suggested that this agent can be an alternative
strategy to the modulation of serotonin, glutamate, and
opioid systems. As yet, no clinical trials have been
conducted.
2.4 Other Pharmacologic Options
2.4.1 Quetiapine
Quetiapine is a second-generation antipsychotic that shows
affinity for various neurotransmitter receptors. Specifically,
the D1 and D2 dopamine receptor, the alpha-1 and alpha-2
adrenergic receptor, and 5-HT1A and 5-HT2 serotonin
receptor subtypes are antagonized. Di Nicola et al. [3]
documented a case of bipolar I disorder with comorbid
compulsive buying disorder and physical exercise addic-
tion that was successfully treated with quetiapine up to
600 mg/day. The authors highlighted that the assessment of
behavioral addictions, such as CBD, in bipolar disorder
patients may have a direct impact on the choice of phar-
macological and psycho-educative interventions. The role
of impulsivity and personality dimensions in bipolar dis-
order is reinforced.
2.4.2 Memantine
In a pilot open-label trial, Grant et al. [50] tested the agent
memantine, an N-methyl-D-aspartate receptor antagonist
that appears to reduce glutamate excitability and improve
impulsive behaviors. Treatment with memantine
10–30 mg/day was associated with diminished impulsive
buying and improvements in cognitive tasks of impulsivity.
In addition, the medication was well-tolerated. The authors
concluded that pharmacologic manipulation of the gluta-
mate system may target the impulsive behavior underlying
CBD in a subtype of patients [50].
3 Discussion
This review shows a predominance of case reports (vs.
clinical trials) and heterogeneous reported pharmacological
treatment options. This may be due to our limited under-
standing of CBD, particularly considerations of classifica-
tion and neurobiological correlates. Discussion on the topic
has raised many questions [37, 38, 41] including the fol-
lowing: is CBD a symptom complex seen in several con-
ditions rather than a separate syndrome? If we consider it
as a distinctive disorder, could it be more related to mood,
obsessive-compulsive, impulse control disorders, or an
addictive spectrum? Is compulsive buying a single con-
struct or has it multiple subtypes or varying roots in the
same individual? Do patients respond preferentially to
medication or to behavior therapy within the same
subtype?
Neurobiological theories have proposed the presence of
a disturbed serotoninergic, dopaminergic, or opioid neu-
rotransmission, which could probably explain the positive
outcome seen with antidepressants or opioid antagonists,
but research to support these assumptions is limited and, to
date, the psychotropic medications used in CBD are sup-
ported mainly by observed or hypothetical similarities with
phenotypes of other treatable disorders and concomitant
comorbidities.
3.1 Compulsive Buying Disorder (CBD) and Mood
Disorders
The prevalence studies showing a high prevalence of
comorbid mood disorders in CBD patients, observations
that shopping and spending have antidepressant effects,
and reports of compulsive buying responding to antide-
pressants have supported a causal link between mood dis-
orders and CBD [14, 22, 34]. However, further studies with
non-depressed patients and cases in which the disorders
showed unrelated outcomes have placed this hypothesis in
question [12, 40]. The role of mood symptoms in the ini-
tiation, continuance, and relief of this disorder warrants
further investigation.
The effectiveness of antidepressants in CBD patients
with and without comorbid mood disorder has been widely
described in case reports, case series, and open-label trials
(Tables 2, 3). However, the only two double-blind trials
conducted showed no statistical differences between the
treated and the placebo groups [37, 38].
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Two case reports suggested that topiramate might be
useful for CBD with comorbid bipolar disorder or
depression, but no controlled studies have been conducted
to confirm these findings [43, 44]. Quetiapine was also
documented to be effective in a single case report of a
patient with comorbid bipolar disorder and was suggested
to be a recommended alternative for similar patients [3].
3.2 CBD and Obsessive Compulsive Disorder
Despite being neither egodystonic nor ritualized, the buy-
ing impulses and buying behavior, respectively, have
similarities to the obsessions and compulsions of OCD, and
some researchers have proposed that CBD can be placed in
the spectrum of disorders linked to OCD [8]. The simi-
larities between these conditions suggested that medication
used to treat OCD would also be useful to treat CBD, and
several SRIs have been tested. However, placebo-con-
trolled studies failed to show statistically significant dif-
ferences between CBD patients treated with fluvoxamine,
an antidepressant shown to be effective in OCD patients,
and placebo [37, 38].
3.3 CBD, Other Impulse Control Disorders,
and Behavioral Addictions
A link has been suggested between CBD and the irre-
sistible impulses and impulse actions of impulse control
disorders and the drug urges and drug use of substance use
disorders [1].
Given the shared common neurobiological mechanisms
between substance and behavior addictions, through the
activation of the reward pathways and the involvement of
multiple neurotransmitter systems (dopaminergic, endoge-
nous opioids, and serotoninergic), opioid antagonists have
been investigated for the treatment of CBD [51].
Improvement was reported, but no clinical trials were
conducted [21, 25].
A recent study has suggested that pharmacologic mod-
ulation of the glutamate system may reduce behaviors
associated with CBD by improving neurocognitive func-
tion targeting inhibiting control mechanisms that result in
shopping behavior despite adverse consequences. The
authors hypothesized that a subtype of patients with CBD
and impaired inhibitory control may respond preferentially
to memantine [50].
3.4 Psychiatric Comorbid Disorders
The studies identified show a high prevalence of comorbid
psychiatric disorders, the concurrent treatment of which
should be considered on an individual basis to ameliorate
the final outcome [41, 52, 53].
To do so, a complete psychiatric history including a
screening of comorbidities is a priority in the treatment of
CBD patients. The previous treatment approaches should
also be assessed and the individual characteristics noted.
Depending on the comorbidity associated, different phar-
macological approaches can be considered. For example,
for a patient with comorbid depression, anxiety, or OCD
features, the antidepressants fluvoxamine or citalopram
may be valid options; in the presence of an impulse control
disorder or substance abuse disorder, topiramate or nal-
trexone may be used.
3.5 CBD and Adjuvant Treatments
According to reports from double-blind studies, psy-
chotherapeutic approaches should be combined. Mueller
et al. [54] conducted a randomized trial to characterize the
efficacy of CBT, and results revealed significant differ-
ences between the groups receiving CBT and the control
groups on the primary outcome variables established. The
improvement was maintained during the 6-month follow-
up, and authors concluded that a disorder-specific cogni-
tive-behavioral intervention can significantly impact com-
pulsive buying behavior [54]. Other non-pharmacological
strategies should also be applied (e.g., self-help programs,
Debtors Anonymous, financial counseling) [2].
3.6 Limitations of Current Studies
Conducting trials in individuals with impulse control dis-
orders is challenging, and limitations of the studies iden-
tified should be noted. Researchers mentioned the use of
different criteria to identify ‘‘illness’’ and response, the
small sample sizes, and the similar drug and placebo
responses as relevant limitations.
Because of a high placebo response, open-label trials
can have a potential bias toward effectiveness, whereas
double-blind trials can measure the true effect of the active
treatment. The high placebo response rate seen in con-
trolled studies is probably explained by a tendency to
reduce the compulsive behavior when greater attention is
given to it. In open-label trials followed by a double-blind
discontinuation phase, the selection of subjects for the
study with a high level of interest in the acquired benefit in
the first open-label phase could have led to the improve-
ment without medication in the double-blind phase [36].
There is limited information on the hypothesis of a dose-
response relationship and the point at which the pharma-
cological treatment can be safely discontinued. The dosage
required for optimal response and maintenance therapy
needs further study.
Additional work is needed to determine which ingredi-
ent of the treatment experimental approach is most
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therapeutic, and more work is needed to show the superi-
ority of medication over placebo with and without other
psychotherapeutic approaches. Longer follow-up pharma-
cologic studies with bigger and less restricted samples are
warranted.
The role of mood symptoms in the course of compulsive
buying symptoms (beginning, maintenance, and remission)
also warrants further investigation.
3.7 Future Research
Future research should focus on the understanding of dis-
ease pathogenesis and pathophysiology. Neurobiological
research on neurotransmitters in CBD, with the measure-
ment of plasma or cerebral spinal fluid levels, would be
useful in this regard.
There is a need for better diagnostic instruments to
standardize clinical criteria in experimental studies, and the
relationship between comorbid conditions and CBD
deserves greater understanding.
As mentioned, there are no adequate data on the longi-
tudinal course of CBD, so longer follow-up placebo-con-
trolled studies should be conducted.
4 Conclusions
The reviewed literature suggest pharmacological inter-
ventions may be effective for CBD. However, the positive
results of pharmacological treatment have not yet been
confirmed in controlled trials.
Most authors agree that the individual characteristics of
the patient (comorbidities, previous medications, self-tol-
erance) will guide the choice of a personalized pharma-
cological treatment. Future research on neurobiological,
psychological, and sociocultural factors will definitely add
to this approach.
Further trials are warranted to find evidence-based
therapeutic recommendations.
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